
WellCare is owned by Centene Corporation (NYSE: CNC), a publicly traded American managed care company headquartered in St. Louis, Missouri. Centene acquired WellCare Health Plans, Inc. in January 2020 for approximately $17.3 billion, making it one of the largest managed care acquisitions in U.S. history. Following the acquisition, Centene consolidated its Medicare Advantage and prescription drug plan offerings under the WellCare brand nationally. WellCare was originally founded in 1985 in Tampa, Florida, and had been publicly traded before the Centene acquisition.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| WellCare | Centene Corporation | Wholly owned |
WellCare was founded in 1985 in Tampa, Florida, as a managed care organization focused on serving Florida's government-sponsored health program populations. The company was established to provide healthcare coverage and care coordination services to Medicaid beneficiaries.
Throughout the late 1980s and 1990s, WellCare expanded its presence in Florida's Medicaid managed care market and added Medicare managed care plans as the Medicare Advantage program expanded. The company went public in 2004 through an IPO on the NASDAQ, later transferring its listing to the NYSE.
In 2007, WellCare faced a major regulatory crisis when federal and state investigators raided the company's headquarters in connection with an investigation into alleged overbilling of Florida's Medicaid and Medicare programs. In 2012, the company paid approximately $218 million to resolve federal and state fraud allegations. The settlement included $137 million to resolve federal False Claims Act allegations and $81 million to resolve state Medicaid fraud claims.
Following the regulatory crisis, WellCare rebuilt its management team, strengthened its compliance and audit functions, and returned to growth. The company expanded through organic growth and acquisitions, including the purchase of Universal American's Medicare Advantage business in 2014 and the acquisition of Care1st Health Plan in 2015, which expanded WellCare's presence in Arizona and California.
In March 2019, Centene Corporation announced its acquisition of WellCare Health Plans in a transaction valued at approximately $17.3 billion. The deal received regulatory approval from state insurance regulators and the Department of Justice, subject to divestitures of certain overlapping health plan operations. The transaction closed on January 23, 2020.
Following the acquisition, Centene consolidated its Medicare offerings under the WellCare brand, giving WellCare a significantly expanded national presence. The brand now serves Medicare beneficiaries across the United States as Centene's primary Medicare brand.
In 2025 and 2026, Centene faced pressure on its Medicaid business due to state contract repricing and eligibility redeterminations following the end of the COVID-19 public health emergency. However, the Medicare Advantage market continued to grow, with approximately 35 million beneficiaries enrolled nationally as of 2026.
Is Centene a subsidiary of another company?
No, Centene Corporation is an independent, publicly traded corporation with no parent company. The company operates independently with its own management structure and board of directors, though it has grown through numerous acquisitions throughout its history, including the transformative $17.3 billion acquisition of WellCare Health Plans in January 2020.
Is Centene publicly traded?
Yes, Centene Corporation is publicly traded on the New York Stock Exchange under the ticker symbol CNC. The company has been publicly traded since its IPO in 2001, when it had three health plans, $327 million in revenue, and 235,000 members. As of 2025, the company is ranked No. 23 on the Fortune 500 list.
When was Centene founded?
Centene traces its origins to 1984 when Elizabeth Brinn founded Managed Health Services as a non profit organization in Milwaukee, Wisconsin. The company was renamed Centene Corporation in 1997 when Michael Neidorff was named President and CEO, and the corporate office was established in St. Louis, Missouri. The company went public in 2001.
Who founded Centene?
Centene was founded by Elizabeth Brinn in 1984 as Managed Health Services, a non profit organization focused on providing healthcare services to Medicaid populations in Milwaukee, Wisconsin. After her death, the organization was converted to a for profit company. Michael Neidorff was named CEO in 1997 and grew Centene from a local health plan to a national healthcare leader over 25 years.
What is Centene's annual revenue?
For fiscal year 2025 (ended December 31, 2025), Centene reported total revenue of $194.8 billion, a 19% increase from $163.1 billion in FY2024. Premium and service revenues were $174.6 billion, up 20% year over year. The company recorded a GAAP net loss of $6.7 billion, primarily due to a $6.7 billion non cash goodwill impairment charge. Adjusted diluted EPS was $2.08, down from $7.17 in FY2024.
What is Centene's market position?
Centene is the largest Medicaid managed care organization in the United States, the longest running carrier in the Health Insurance Marketplace, and a national leader in Medicare Prescription Drug Plans. The company serves 27.6 million members across all 50 states as of December 31, 2025, with revenue from Medicaid (57%), Commercial (21%), Medicare (19%), and Other (3%) segments. Centene is ranked No. 23 on the Fortune 500 and No. 42 on the Fortune Global 500.
Who is Centene's CEO?
Sarah M. London has served as Chief Executive Officer of Centene Corporation since 2022. She is the first woman to lead the company. Under her leadership, Centene has refocused on three core lines of business: Medicaid, Medicare, and the Health Insurance Marketplace. In 2025, London navigated the company through significant challenges including the $6.7 billion goodwill impairment, Marketplace risk adjustment shortfall, and elevated Medicaid medical cost trends.
What is the WellCare acquisition?
In January 2020, Centene completed the acquisition of WellCare Health Plans in a $17.3 billion transaction (enterprise value). WellCare shareholders received 3.38 shares of Centene common stock and $120 in cash for each share of WellCare common stock. The acquisition made Centene a nationwide company serving all 50 states with approximately 24 million members, expanded its Medicare platform, and extended its Medicaid offerings. WellCare became a wholly owned subsidiary of Centene and continues to operate as a brand under the Centene umbrella.
WellCare operates under Centene's corporate sustainability framework, focusing on healthcare access, community health programs, and health equity initiatives.
WellCare maintains programs to improve healthcare access for underserved populations, including Medicare beneficiaries with complex health needs and limited resources. The company's health equity initiatives focus on reducing healthcare disparities through culturally competent care, language access services, and targeted outreach to vulnerable populations.
WellCare invests in community-based health initiatives that address social determinants of health, including nutrition assistance, transportation services, and housing support for Medicare beneficiaries. The company partners with local organizations to improve health outcomes and reduce healthcare costs through preventive care.
WellCare has developed telehealth capabilities and digital health tools to improve access to care, particularly for members with mobility limitations or those in rural areas. The company's digital platforms enable virtual care visits, remote monitoring, and digital medication management.
Following the 2007 regulatory crisis, WellCare implemented robust compliance programs, audit functions, and ethical business practices. The company maintains transparent communication with members, providers, and regulators, along with rigorous adherence to healthcare regulations and anti-fraud measures.
WellCare has consistently achieved high Medicare Advantage star ratings from the Centers for Medicare and Medicaid Services (CMS). These ratings measure plan performance on quality, access, and customer satisfaction, with WellCare plans frequently receiving 4-5 star ratings in various markets.
WellCare has earned accreditation from the National Committee for Quality Assurance (NCQA) for its Medicaid and Medicare Advantage health plans, demonstrating compliance with rigorous quality standards for managed care operations.
WellCare has received awards for its community health programs and partnerships with organizations serving elderly and disabled populations. The company's preventive care initiatives and health education programs have been recognized by state health departments and healthcare advocacy organizations.
WellCare's telehealth and digital health initiatives have received recognition from healthcare technology organizations for improving access to care for Medicare beneficiaries.
2007 Regulatory Crisis and Fraud Investigation: The most significant controversy in WellCare's history occurred in 2007 when federal and state investigators raided the company's Tampa headquarters in connection with an investigation into alleged overbilling of Florida's Medicaid and Medicare programs. The investigation focused on allegations that WellCare had inflated claims and billed for services not provided, particularly related to behavioral health services.
$218 Million Settlement (2012): WellCare paid approximately $218 million to resolve federal and state fraud allegations stemming from the 2007 investigation. The settlement included $137 million to resolve federal False Claims Act allegations and $81 million to resolve state Medicaid fraud claims. The regulatory crisis led to substantial management changes, including the departure of key executives and the appointment of new leadership focused on compliance reform.
Centene Acquisition Integration Challenges: Following the 2020 acquisition, WellCare faced integration challenges related to consolidating multiple Medicare brands under the WellCare name and aligning operations with Centene's corporate structure. Centene divested its Illinois Medicaid and Medicare Advantage plans, and WellCare divested its Missouri Medicaid and Medicare Advantage plans and its Nebraska Medicaid plan, to address antitrust concerns. These market exits disrupted member coverage and required complex transition processes.
Medicare Advantage Compliance: Like other Medicare Advantage insurers, WellCare has faced scrutiny from CMS regarding compliance with Medicare Advantage program requirements, including risk adjustment documentation and coverage determination processes. The company has invested in compliance programs to address these regulatory requirements.
Provider Network Disputes: WellCare has faced occasional disputes with healthcare providers over reimbursement rates and network participation agreements. These disputes have sometimes resulted in temporary disruptions in provider access for members.
Data Privacy and Security: WellCare handles sensitive member health information and faces ongoing challenges related to data privacy, cybersecurity, and compliance with healthcare privacy regulations including HIPAA.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Elevance Health | USA | 2024 | Mass market | United states | All-ages | |
| Cvs Health | United States | 1853 | Mass market | North america | All Genders | |
| Cigna | USA | 1982 | Mass market | United states | All Genders | |
| Cvs Health | USA | 1963 | Mass market | United states | All Genders | |
| Cvs Health | USA | 2000 | Mass market | United states | All-consumers | |
| Centene | USA | 2008 | Mass market | United states | All Genders |
Healthcare PharmaceuticalsOwned by Elevance Health Inc.
Elevance Health's government health plan brand for Medicaid, CHIP, and Medicare in states where Anthem Blue Cross Blue Shield does not operate, rebranded from Amerigroup in January 2024.
Healthcare PharmaceuticalsOwned by CVS Health Corporation
American managed care and health insurance company offering medical, dental, pharmacy, and behavioral health plans, operating as a subsidiary of CVS Health Corporation.
Healthcare PharmaceuticalsOwned by The Cigna Group
American health insurance brand providing medical coverage, health plans, and wellness services for individuals, families, and employers through The Cigna Group.
Healthcare PharmaceuticalsOwned by CVS Health Corporation
American pharmacy retail chain and one of the largest pharmacy networks in the United States, owned by CVS Health.
Healthcare PharmaceuticalsOwned by CVS Health Corporation
American retail healthcare clinic chain operating over 1,100 locations within CVS Pharmacy stores, owned by CVS Health. Provides urgent care, vaccinations, chronic disease management, and virtual care services.
Healthcare PharmaceuticalsOwned by Centene Corporation
Centene Corporation's Florida-based health insurance brand providing Medicaid managed care, Long Term Care, Ambetter marketplace plans, and Medicare Advantage to Florida residents.
Market Positioning: WellCare competes with 6 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Centene Corporation, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Herbalife Ltd.
Global nutrition and weight-management brand owned by Herbalife Ltd. and sold through independent distributors in more than 90 markets.
Herbalife operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
Pharmacy Direct is privately owned, unlike WellCare which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
GE HealthCare operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by GoodRx Holdings, Inc.
American healthcare technology platform providing prescription drug price comparison, discount coupons, and telehealth services to help consumers find affordable healthcare options.
GoodRx operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Alcon Inc.
Independent publicly traded global eye care company headquartered in Geneva, Switzerland, specializing in surgical equipment, contact lenses, and ophthalmic products. Spun off from Novartis in April 2019.
Alcon operates independently without a large parent corporation.
Owned by Menicon Co., Ltd.
Japan's first and largest contact lens manufacturer, founded in 1951 in Nagoya. Known for rigid gas permeable lenses, orthokeratology, and expanding daily disposable silicone hydrogel products.
Menicon operates independently without a large parent corporation.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.